Skip to Main Content

The shoe is on the other foot, so to speak.

For the past few years, the Food and Drug Administration has tried harder to scrutinize Chinese pharmaceutical suppliers over widespread quality control concerns. Now, though, a Chinese government agency has found problems with a U.S. company that does contract manufacturing work for Bristol Myers Squibb (BMY) and, as a result, shipment of a key product to China has been suspended.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.